Processing your request

please wait...

Case Page


Case Status:    DISMISSED    
On or around 12/12/2018 (Notice of voluntarily dismissal)

Filing Date: December 12, 2018

According to the Complaint, bluebird bio, inc. ("bluebird" or the Company) is a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer. The Company is primarily focused on the treatment of sickle cell disease (“SCD”). SCD is a serious, progressively debilitating and life-threatening genetic disease that results from production of abnormal sickle hemoglobin (“HbS”), which leads to sickled red blood cells (“RBCs”) and hemolysis. As a result of this abnormal hemoglobin, many affected individuals live with severe anemia and vaso-occlusive events which include severe, recurrent pain crises that lead to organ damage and shortened life span.

The Company is conducting five clinical studies of its LentiGlobin product candidate, designed to treat SCD, with the stated goal of filing for regulatory approval in the US and EU for different genotypes of TDT and for severe SCD. The Company’s five studies are: (i) a Phase I/II study in the United States, Australia, and Thailand to evaluate its safety and efficacy in the treatment of subjects with TDT, called the Northstar Study (HGB-204); (ii) a multi-site, international, Phase III study to evaluate its safety and efficacy in the treatment of subjects with TDT and a non-?0
/?0 genotype, called the Northstar-2 Study (HGB-207); (iii) a multi-site, international, Phase III study for the treatment of subjects with TDT and a ?0 /?0 genotype, called the Northstar 3 Study (HGB-212); (iv) a single-center Phase I/II study in France to evaluate its safety and efficacy in the treatment of subjects with TDT or with severe SCD (HGB-205); and (v) a multi-site Phase I study in the United States to evaluate its safety and efficacy in the treatment of subjects with severe SCD (HGB-206).

Following treatment with LentiGlobin in the Northstar studies, patients are monitored for production of HbAT87Q, which is gene therapy derived-hemoglobin. The production of HbAT87Q increases the overall hemoglobin level in patients with the goal of reducing or eliminating the need for transfusions.

Throughout the Class Period, the Company stated that its various LentiGlobin studies, including HGB-205, would form the basis of its regulatory approval applications.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. The Complaint specifically alleges that Defendants made false and/or misleading statements and/or failed to disclose that: (i) LentiGlobin when used to treat severe SCD did not produce as much anti-sickling hemoglobin as the Company had previously reported; (ii) accordingly, the Company’s LentiGlobin product was not as effective as previously reported; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

This case was voluntarily dismissed on December 12, 2018.


Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States


Ticker Symbol: BLUE
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: D. Massachusetts
DOCKET #: 18-CV-12556
JUDGE: Hon. Mark L. Wolf
DATE FILED: 12/12/2018
CLASS PERIOD END: 11/29/2018
  1. Andrews DeValerio LLP
  2. Pomerantz LLP (New York)
No Document Title Filing Date
—Reference Complaint Complaint Related Data is not available
—Related District Court Filings Data is not available